Trial Profile
Add-on or switch to repaglinide for type 2 diabetes with sitagliptin: Randomized controlled open-labelled trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2017
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Feb 2017 Status changed from recruiting to completed.
- 09 Aug 2013 New trial record